Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics

Vanessa Rausch, Li Liu, Georgios Kallifatidis, Bernd Baumann, Jürgen Mattern, Jury Gladkich, Thomas Wirth, Peter Schemmer, Markus W. Büchler, Margot Zöller, Alexei V. Salnikov, Ingrid Herr

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Recent evidence suggests that pancreatic cancer and other solid tumors contain a subset of tumorigenic cells capable of extensive self-renewal that contribute to metastasis and treatment resistance. Sorafenib (SO) is a promising new multikinase inhibitor for treatment of advanced kidney and liver cancers. We report here targeting of pancreatic cancer stem cells (CSC) by SO and the development of a strategy to enhance this effect. Although SO administration diminished clonogenicity, spheroid formation, aldehyde dehydrogenase 1 (ALDH1) activity, growth on immunodeficient mice, proliferation, and angiogenesis and induced apoptosis, we observed SO-induced activation of NF-κB associated with survival and regrowth of spheroids. For enhanced elimination of CSC characteristics by SO, we cotreated cells with sulforaphane (SF). This broccoli isothiocyanate was recently described to eliminate pancreatic CSCs by downregulation of NF-κB activity without inducing toxic side effects. On combination treatment, SF completely eradicated SO-induced NF-κB binding, which was associated with abrogated clonogenicity, spheroid formation, ALDH1 activity, migratory capacity, and induction of apoptosis. In vivo, combination therapy reduced the tumor size in a synergistic manner. This was due to induction of apoptosis, inhibition of proliferation and angiogenesis, and downregulation of SO-induced expression of proteins involved in epithelial-mesenchymal transition. Our data suggest that SF may be suited to increase targeting of CSCs by SO.

Original languageEnglish (US)
Pages (from-to)5004-5013
Number of pages10
JournalCancer Research
Volume70
Issue number12
DOIs
StatePublished - Jun 15 2010

Fingerprint

Neoplastic Stem Cells
Pancreatic Neoplasms
Apoptosis
Down-Regulation
Epithelial-Mesenchymal Transition
sorafenib
sulforafan
Kidney Neoplasms
Poisons
Brassica
Liver Neoplasms
Neoplasms
Neoplasm Metastasis
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. / Rausch, Vanessa; Liu, Li; Kallifatidis, Georgios; Baumann, Bernd; Mattern, Jürgen; Gladkich, Jury; Wirth, Thomas; Schemmer, Peter; Büchler, Markus W.; Zöller, Margot; Salnikov, Alexei V.; Herr, Ingrid.

In: Cancer Research, Vol. 70, No. 12, 15.06.2010, p. 5004-5013.

Research output: Contribution to journalArticle

Rausch, V, Liu, L, Kallifatidis, G, Baumann, B, Mattern, J, Gladkich, J, Wirth, T, Schemmer, P, Büchler, MW, Zöller, M, Salnikov, AV & Herr, I 2010, 'Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics', Cancer Research, vol. 70, no. 12, pp. 5004-5013. https://doi.org/10.1158/0008-5472.CAN-10-0066
Rausch, Vanessa ; Liu, Li ; Kallifatidis, Georgios ; Baumann, Bernd ; Mattern, Jürgen ; Gladkich, Jury ; Wirth, Thomas ; Schemmer, Peter ; Büchler, Markus W. ; Zöller, Margot ; Salnikov, Alexei V. ; Herr, Ingrid. / Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. In: Cancer Research. 2010 ; Vol. 70, No. 12. pp. 5004-5013.
@article{51c78191fcc345f5a1144c0a5a61ee8b,
title = "Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics",
abstract = "Recent evidence suggests that pancreatic cancer and other solid tumors contain a subset of tumorigenic cells capable of extensive self-renewal that contribute to metastasis and treatment resistance. Sorafenib (SO) is a promising new multikinase inhibitor for treatment of advanced kidney and liver cancers. We report here targeting of pancreatic cancer stem cells (CSC) by SO and the development of a strategy to enhance this effect. Although SO administration diminished clonogenicity, spheroid formation, aldehyde dehydrogenase 1 (ALDH1) activity, growth on immunodeficient mice, proliferation, and angiogenesis and induced apoptosis, we observed SO-induced activation of NF-κB associated with survival and regrowth of spheroids. For enhanced elimination of CSC characteristics by SO, we cotreated cells with sulforaphane (SF). This broccoli isothiocyanate was recently described to eliminate pancreatic CSCs by downregulation of NF-κB activity without inducing toxic side effects. On combination treatment, SF completely eradicated SO-induced NF-κB binding, which was associated with abrogated clonogenicity, spheroid formation, ALDH1 activity, migratory capacity, and induction of apoptosis. In vivo, combination therapy reduced the tumor size in a synergistic manner. This was due to induction of apoptosis, inhibition of proliferation and angiogenesis, and downregulation of SO-induced expression of proteins involved in epithelial-mesenchymal transition. Our data suggest that SF may be suited to increase targeting of CSCs by SO.",
author = "Vanessa Rausch and Li Liu and Georgios Kallifatidis and Bernd Baumann and J{\"u}rgen Mattern and Jury Gladkich and Thomas Wirth and Peter Schemmer and B{\"u}chler, {Markus W.} and Margot Z{\"o}ller and Salnikov, {Alexei V.} and Ingrid Herr",
year = "2010",
month = "6",
day = "15",
doi = "10.1158/0008-5472.CAN-10-0066",
language = "English (US)",
volume = "70",
pages = "5004--5013",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics

AU - Rausch, Vanessa

AU - Liu, Li

AU - Kallifatidis, Georgios

AU - Baumann, Bernd

AU - Mattern, Jürgen

AU - Gladkich, Jury

AU - Wirth, Thomas

AU - Schemmer, Peter

AU - Büchler, Markus W.

AU - Zöller, Margot

AU - Salnikov, Alexei V.

AU - Herr, Ingrid

PY - 2010/6/15

Y1 - 2010/6/15

N2 - Recent evidence suggests that pancreatic cancer and other solid tumors contain a subset of tumorigenic cells capable of extensive self-renewal that contribute to metastasis and treatment resistance. Sorafenib (SO) is a promising new multikinase inhibitor for treatment of advanced kidney and liver cancers. We report here targeting of pancreatic cancer stem cells (CSC) by SO and the development of a strategy to enhance this effect. Although SO administration diminished clonogenicity, spheroid formation, aldehyde dehydrogenase 1 (ALDH1) activity, growth on immunodeficient mice, proliferation, and angiogenesis and induced apoptosis, we observed SO-induced activation of NF-κB associated with survival and regrowth of spheroids. For enhanced elimination of CSC characteristics by SO, we cotreated cells with sulforaphane (SF). This broccoli isothiocyanate was recently described to eliminate pancreatic CSCs by downregulation of NF-κB activity without inducing toxic side effects. On combination treatment, SF completely eradicated SO-induced NF-κB binding, which was associated with abrogated clonogenicity, spheroid formation, ALDH1 activity, migratory capacity, and induction of apoptosis. In vivo, combination therapy reduced the tumor size in a synergistic manner. This was due to induction of apoptosis, inhibition of proliferation and angiogenesis, and downregulation of SO-induced expression of proteins involved in epithelial-mesenchymal transition. Our data suggest that SF may be suited to increase targeting of CSCs by SO.

AB - Recent evidence suggests that pancreatic cancer and other solid tumors contain a subset of tumorigenic cells capable of extensive self-renewal that contribute to metastasis and treatment resistance. Sorafenib (SO) is a promising new multikinase inhibitor for treatment of advanced kidney and liver cancers. We report here targeting of pancreatic cancer stem cells (CSC) by SO and the development of a strategy to enhance this effect. Although SO administration diminished clonogenicity, spheroid formation, aldehyde dehydrogenase 1 (ALDH1) activity, growth on immunodeficient mice, proliferation, and angiogenesis and induced apoptosis, we observed SO-induced activation of NF-κB associated with survival and regrowth of spheroids. For enhanced elimination of CSC characteristics by SO, we cotreated cells with sulforaphane (SF). This broccoli isothiocyanate was recently described to eliminate pancreatic CSCs by downregulation of NF-κB activity without inducing toxic side effects. On combination treatment, SF completely eradicated SO-induced NF-κB binding, which was associated with abrogated clonogenicity, spheroid formation, ALDH1 activity, migratory capacity, and induction of apoptosis. In vivo, combination therapy reduced the tumor size in a synergistic manner. This was due to induction of apoptosis, inhibition of proliferation and angiogenesis, and downregulation of SO-induced expression of proteins involved in epithelial-mesenchymal transition. Our data suggest that SF may be suited to increase targeting of CSCs by SO.

UR - http://www.scopus.com/inward/record.url?scp=77953798273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953798273&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-0066

DO - 10.1158/0008-5472.CAN-10-0066

M3 - Article

C2 - 20530687

AN - SCOPUS:77953798273

VL - 70

SP - 5004

EP - 5013

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 12

ER -